EUCTR2011-005179-18-SE进行中（未招募）1 期
A Double-blind, Placebo-controlled Study of Cariprazine (RGH-188) asAdjunctive Therapy In Major Depressive Disorder.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 819
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be eligible to participate in the study, patients must meet the
- •following criteria:
- •1. Written informed consent, signed or thumbprinted (only if allowed by
- •regulations), obtained from the patient before the initiation of any
- •study-specific
- •2. Male or female outpatients 18 to 65 years of age, inclusive
- •3. Currently meet the DSM-IV-TR criteria for MDD without psychotic
- •features based
- •on the Structured Clinical Interview for Diagnostic Statistic Manual of
- •Mental Health
- •Disorders, Fourth Edition (SCID), with a current major depressive
- •episode of at least
- •8 weeks and not exceeding 24 months in duration at Visit 1
- •4. Ongoing inadequate response to protocol allowed ADT (bupropion,
- •citalopram,
- •desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline,
- •venlafaxine, or
- •vilazodone) administered at adequate dose and duration in accordance
- •XML File Identifier: FTghhKCzrbTe51LNLfPc6oXpt74=
- •XML File Identifier: EyBIDO9jDoz4RpZr1nNSEG1ScS4=
- •respective package insert, documented in the Antidepressant Treatment
- •History Form
- •(ATHF) with a resistance rating of = 3 and a global confidence score of =
- •5. Montgomery-Asberg Depression Rating Scale (MADRS) total score =
- •Screening (Visit 1) and Baseline (Visit 2)
- •6. Normal physical examination findings, clinical laboratory results, and
- •electrocardiogram (ECG) results from Screening (Visit 1) or abnormal
- •judged not clinically significant by the PI and documented as such in the
- •7. Body mass index between 18 and 40, inclusive
- •8. If female of child bearing potential, have a negative serum ß-human
- •gonadotropin (ß-hCG]) pregnancy test
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 810
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Psychiatric Criteria:
- •1. Principal DSM-IV-TR–based diagnosis of an axis I disorder, other than
- •any axis I disorder other than MDD that was the primary focus of
- •treatment within
- •6 months before Visit 1 (secondary diagnoses of comorbid generalized
- •disorder, social anxiety disorder, or specific phobias are acceptable)
- •2. History of meeting DSM-IV-TR criteria for:
- •a. Any depressive episode with psychotic or catatonic features
- •b. Any manic, hypomanic or mixed episode, including bipolar disorder
- •substance-induced (eg, antidepressant-induced) manic, hypomanic or
- •c. Schizophrenia, schizoaffective, or other psychotic disorder
- •d. Panic disorder, with or without agoraphobia
- •e. Obsessive-Compulsive disorder
- •f. Bulimia or Anorexia Nervosa
- •g. Dementia, amnesic, or other cognitive disorder
- •h. Mental retardation
- •3. Meeting full DSM-IV-TR criteria for MDD with seasonal pattern AND
- •patient's season of remission would occur during the study.
- •4. DSM-IV-TR–based diagnosis of borderline or antisocial personality
- •disorder or other
- •axis II disorder of sufficient severity to interfere with participation in
- •5. History of meeting DSM-IV-TR criteria for alcohol or substance abuse
- •or dependence
- •(other than nicotine or caffeine) within the 6 months before Visit 1
- •6. Positive result on blood alcohol test or for any prohibited medication
- •on the urine
- •drug screen with the following stipulations:
- •? Patients with a positive urine drug screen for cannabinoids,
- •barbiturates, opiates,
- •amphetamines, or benzodiazepines may be allowed in the study provided
- •XML File Identifier: FTghhKCzrbTe51LNLfPc6oXpt74=
- •drug was used for a legitimate medical purpose and the use of such
- •products can
- •XML File Identifier: EyBIDO9jDoz4RpZr1nNSEG1ScS4=
- •be discontinued (documented by a negative repeat test) before
- •participation
- •beyond screening
- •? Medically appropriate episodic use (up to 3 days) of narcotic analgesics
- •medical indications is allowed
- •? Discussion with Medical Monitor is recommended in any potential
- •listed above
- •? Positive results for methadone, phencyclidine, and cocaine are
- •exclusionary with
- •no exceptions
- •7. Suicide risk, as determined by meeting any of the following criteria:
- •? A suicide attempt within the past year
- •? Significant risk, as judged by the PI, based on the psychiatric interview
- •information collected in the Columbia–Suicide Severity Rating Scale
- •Visit 1 or Visit 2
- •? MADRS Item 10 score = 5 at Visit 1 or Visit 2
- 另有 20 项未显示
研究者
相似试验
进行中（未招募）
不适用
Safety and Efficacy of Cariprazine as an Adjunctive to AntidepressantTherapy in Major Depressive DisorderMajor Depressive DisorderEUCTR2011-005179-18-SKForest Research Institute, Inc810
进行中（未招募）
不适用
Safety and Efficacy of Cariprazine as an Adjunctive to AntidepressantTherapy in Major Depressive DisorderMajor Depressive DisorderEUCTR2011-005179-18-EEForest Research Institute, Inc810
进行中（未招募）
不适用
Safety and Efficacy of Cariprazine as an Adjunctive to AntidepressantTherapy in Major Depressive DisorderMajor Depressive DisorderEUCTR2011-005179-18-FIForest Research Institute, Inc810
进行中（未招募）
4 期
clinical trial on Papaya leaf extract in cancer patients for increasing platelet let countsCTRI/2018/01/011144Micro Labs Ltd
尚未招募
4 期
Clinical Trial On Papaya Leaf Extract In Cancer Patients For Increasing Platelet Let CountsCTRI/2019/01/017209Katra Phytochem India Pvt Ltd